News | October 29, 2021
Zydus Wellness PAT at Rs. 21.47 cr. in Q2FY22
Zydus Wellness Limited has reported consolidated financial results for the period ended September 30, 2021
Zydus Wellness Limited has reported consolidated financial results for the period ended September 30, 2021
Incidences of Non-alcoholic Fatty Liver Disease (NAFLD) have been rising exponentially worldwide and are associated with co-morbidities including obesity, diabetes, hypertension and metabolic disorders
The rolling submission to the U.S. FDA will begin in the fourth quarter of this year
Zydus' Apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy
The purchaser is a part of the portfolio companies of PE firm True North. The said transaction is not a related party transaction.
The medicine helps restore the balance of certain natural substances (serotonin) in the brain
The three-dose vaccine approved for EUA contains 2mg for each dose, whereas the two-dose plan will have 3mg in each dose.
The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.
Zydus’ Sitagliptin base contains the active moiety Sitagliptin in a different form than used in the branded reference product, Januvia (Sitagliptin Phosphate)
Zydus was the first to file an ANDA for Tofacitinib extended-release tablets 22 mg and currently holds 180-day exclusivity on this strength
Subscribe To Our Newsletter & Stay Updated
